274 related articles for article (PubMed ID: 33444163)
1. HbA
Bethel MA; Diaz R; Castellana N; Bhattacharya I; Gerstein HC; Lakshmanan MC
Diabetes Care; 2021 Jan; 44(1):290-296. PubMed ID: 33444163
[TBL] [Abstract][Full Text] [Related]
2. Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression.
Maiorino MI; Longo M; Scappaticcio L; Bellastella G; Chiodini P; Esposito K; Giugliano D
Cardiovasc Diabetol; 2021 Oct; 20(1):210. PubMed ID: 34663316
[TBL] [Abstract][Full Text] [Related]
3. Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta-analysis.
Mantsiou C; Karagiannis T; Kakotrichi P; Malandris K; Avgerinos I; Liakos A; Tsapas A; Bekiari E
Diabetes Obes Metab; 2020 Oct; 22(10):1857-1868. PubMed ID: 32476254
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and safety of glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes: evidence from a retrospective real-world study.
Jiang Y; Bai HS; Liu GX; Wang SY; Yin L; Hou ZT; Zhao CY; Fan GJ
Front Endocrinol (Lausanne); 2024; 15():1347684. PubMed ID: 38524632
[TBL] [Abstract][Full Text] [Related]
6. Addition of or switch to insulin therapy in people treated with glucagon-like peptide-1 receptor agonists: A real-world study in 66 583 patients.
Montvida O; Klein K; Kumar S; Khunti K; Paul SK
Diabetes Obes Metab; 2017 Jan; 19(1):108-117. PubMed ID: 27629433
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Short- and Long-Acting Glucagon-Like Peptide 1 Receptor Agonists on a Background of Basal Insulin in Type 2 Diabetes: A Meta-analysis.
Huthmacher JA; Meier JJ; Nauck MA
Diabetes Care; 2020 Sep; 43(9):2303-2312. PubMed ID: 32910778
[TBL] [Abstract][Full Text] [Related]
8. Similar effectiveness of dapagliflozin and GLP-1 receptor agonists concerning combined endpoints in routine clinical practice: A multicentre retrospective study.
Fadini GP; Sciannameo V; Franzetti I; Bottigliengo D; D'Angelo P; Vinci C; Berchialla P; Arena S; Buzzetti R; Avogaro A;
Diabetes Obes Metab; 2019 Aug; 21(8):1886-1894. PubMed ID: 30985052
[TBL] [Abstract][Full Text] [Related]
9. Glucagon-Like Peptide-1 Receptor Agonist and Risk of Diabetic Retinopathy in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Placebo-Controlled Trials.
Jiao X; Peng P; Zhang Q; Shen Y
Clin Drug Investig; 2023 Dec; 43(12):915-926. PubMed ID: 37938535
[TBL] [Abstract][Full Text] [Related]
10. Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: results of a systematic meta-analysis and meta-regression.
Katout M; Zhu H; Rutsky J; Shah P; Brook RD; Zhong J; Rajagopalan S
Am J Hypertens; 2014 Jan; 27(1):130-9. PubMed ID: 24263424
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials.
Sattar N; Lee MMY; Kristensen SL; Branch KRH; Del Prato S; Khurmi NS; Lam CSP; Lopes RD; McMurray JJV; Pratley RE; Rosenstock J; Gerstein HC
Lancet Diabetes Endocrinol; 2021 Oct; 9(10):653-662. PubMed ID: 34425083
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: A meta-analysis.
Castellana M; Cignarelli A; Brescia F; Perrini S; Natalicchio A; Laviola L; Giorgino F
Sci Rep; 2019 Dec; 9(1):19351. PubMed ID: 31852920
[TBL] [Abstract][Full Text] [Related]
13. Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study.
Lugner M; Sattar N; Miftaraj M; Ekelund J; Franzén S; Svensson AM; Eliasson B
Cardiovasc Diabetol; 2021 Mar; 20(1):67. PubMed ID: 33752680
[TBL] [Abstract][Full Text] [Related]
14. The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs.
Giugliano D; Longo M; Signoriello S; Maiorino MI; Solerte B; Chiodini P; Esposito K
Cardiovasc Diabetol; 2022 Mar; 21(1):42. PubMed ID: 35296336
[TBL] [Abstract][Full Text] [Related]
15. Glucagon-like Peptide 1 Receptor Agonists, Diabetic Retinopathy and Angiogenesis: The AngioSafe Type 2 Diabetes Study.
Gaborit B; Julla JB; Besbes S; Proust M; Vincentelli C; Alos B; Ancel P; Alzaid F; Garcia R; Mailly P; Sabatier F; Righini M; Gascon P; Matonti F; Houssays M; Goumidi L; Vignaud L; Guillonneau X; Erginay A; Dupas B; Marie-Louise J; Autié M; Vidal-Trecan T; Riveline JP; Venteclef N; Massin P; Muller L; Dutour A; Gautier JF; Germain S
J Clin Endocrinol Metab; 2020 Apr; 105(4):. PubMed ID: 31589290
[TBL] [Abstract][Full Text] [Related]
16. Glucagon-Like Peptide-1 Receptor Agonists in Adult Patients With Type 2 Diabetes: Review of Cardiovascular Outcome Trials.
Varin EM; McLean BA; Lovshin JA
Can J Diabetes; 2020 Feb; 44(1):68-77. PubMed ID: 31699625
[TBL] [Abstract][Full Text] [Related]
17. Effect of Hemoglobin A1c Reduction or Weight Reduction on Blood Pressure in Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Treatment in Type 2 Diabetes Mellitus: A Meta-Analysis.
Hu M; Cai X; Yang W; Zhang S; Nie L; Ji L
J Am Heart Assoc; 2020 Apr; 9(7):e015323. PubMed ID: 32223390
[TBL] [Abstract][Full Text] [Related]
18. Real-world impact on monthly glucose-lowering medication cost, HbA
Rose TN; Jacobs ML; Reid DJ; Bouwmeester CJ; Conley MP; Fatehi B; Matta TM; Barr JT
J Am Pharm Assoc (2003); 2020; 60(1):31-38.e1. PubMed ID: 31611005
[TBL] [Abstract][Full Text] [Related]
19. Real-world use of glucagon-like peptide-1 receptor agonists in Japanese patients with type 2 diabetes: A retrospective database study (DEFINE-G).
Ohsugi M; Eguchi K; Thietje Mortensen J; Yamamoto Y; Ueki K
Diabetes Res Clin Pract; 2023 Sep; 203():110841. PubMed ID: 37481115
[TBL] [Abstract][Full Text] [Related]
20. GLP-1 receptor agonist added to insulin versus basal-plus or basal-bolus insulin therapy in type 2 diabetes: A systematic review and meta-analysis.
Castellana M; Cignarelli A; Brescia F; Laviola L; Giorgino F
Diabetes Metab Res Rev; 2019 Jan; 35(1):e3082. PubMed ID: 30270567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
